News | 03.17.20
Interim Study Results Presented for Artio Medical’s Endura Embolization System
March 17, 2020—Artio Medical announced that interim nonclinical study results for the company’s Endura embolization system were presented by Blaise Baxter, MD, at the ABC-WIN (Anatomy-Biology-Clinical Correlations–Working Group in Interventional Neuroradiology) seminar held January 12–17 in Val d'Isere, France.
News | 03.12.20
SIR Position Statement Guides Use of Endovascular Interventions in Trauma Care
March 12, 2020—The Society of Interventional Radiology (SIR) recently announced the publication of a position statement outlining the parameters trauma centers need to meet when using endovascular interventions to treat cases of traumatic injury.
News | 02.03.20
Indication Approved for Merit Medical’s EmboCube and Torpedo for Embolization to Occlude Blood Flow
February 3, 2020—Merit Medical Systems, Inc. announced that both its EmboCube and Torpedo devices are now FDA indicated for the embolization of blood vessels to occlude blood flow, which helps control bleeding and hemorrhaging in the peripheral vasculature.
News | 12.16.19
Randomized, Sham-Controlled Trial Demonstrates Efficacy of Prostate Artery Embolization for Symptomatic BPH
December 16, 2019—A study published online ahead of print in European Urology evaluating prostatic artery embolization (PAE) for symptomatic benign prostatic hyperplasia (BPH) found that the “clearly superior efficacy” of PAE compared with a sham procedure supports the use of PAE in patients with typical symptoms associated with BPH.
News | 07.02.19
Varian to Acquire Oncozene and Embozene Embolic Bead Lines From Boston Scientific
July 2, 2019—Varian Medical Systems, Inc. continued to expand its interventional oncology/embolic portfolio, announcing plans to acquire Boston Scientific's drug-loadable microsphere and bland embolic bead product lines for treating arteriovenous malformations and hypervascular tumors.
News | 06.13.19
QXMédical Licenses Bioresorbable Embolic Technology From University of Minnesota
June 10, 2019—QXMédical announced that it has acquired the worldwide exclusive rights to the bioresorbable embolic technology developed at the University of Minnesota for resorbable and drug-loadable microspheres and hydrogels to be marketed to interventional radiologists and oncologists to occlude vessels for a variety of clinical indications.
News | 05.30.19
Study Compares Different Sizes of Microspheres for Embolization to Treat BPH
May 30, 2019—Results of a single-center study comparing the safety and efficacy of prostatic artery embolization (PAE) using trisacryl gelatin microspheres of different sizes for treatment of benign prostatic hyperplasia (BPH) were published by Daniel Torres, MD, et al in Journal of Vascular and Interventional Radiology (JVIR; 2019;30:638–644).
News | 04.19.19
Multisociety Position Statement Supports PAE to Treat Lower Urinary Tract Symptoms Attributed to BPH
April 19, 2019—A multisociety consensus position statement on prostate artery embolization (PAE) for treatment of lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH) was published by Justin P. McWilliams, MD, et al in Journal of Vascular and Interventional Radiology (JVIR).
US Device Guide
This Device Guides offers a searchable, comprehensive listing of the available vascular interventional devices in the United States.
European Device Guide
This Device Guides offers a searchable, comprehensive listing of the available vascular interventional devices in Europe.